Veracyte announced that data published in the International Journal of Radiation Oncology, Biology, Physics demonstrate that the company’s Decipher Prostate Genomic Classifier can improve risk stratification among men with clinically high-risk prostate cancer. The data, from a pre-specified analysis of three phase 3 trials, represent the first validation of any gene-expression biomarker on pre-treatment biopsy samples from prospective randomized trials, and suggest the Decipher test provides clinically useful prognostic information to help personalize shared treatment decision-making. Approximately 30% of men with newly diagnosed localized prostate cancer present with high-risk disease, meaning they have an increased risk of disease recurrence, metastasis and death compared to men with lower-risk disease. However, previous studies have shown that more than 70% of men with high-risk prostate cancer who receive standard-of-care definitive radiotherapy and long-term androgen deprivation therapy will never develop metastatic disease.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on VCYT:
- ‘Stay Long and Strong’: Billionaire Ken Fisher Snaps Up These 2 ‘Strong Buy’ Stocks
- Veracyte to present multiple Decipher urologic testing abstracts at ASCO
- Veracyte: Data show Afirma testing may help patients with thyroid nodules care
- Exagen elects Nova as Executive Chair of board of directors
- Veracyte downgraded to Market Perform from Outperform at Raymond James